Cargando…
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
Combination therapy with α-CTLA-4 and α-PD-1 has shown significant clinical responses in different types of cancer. However, the underlying mechanisms remain elusive. Here, combining detailed analysis of human tumour samples with preclinical tumour models, we report that concomitant blockade of CTLA...
Autores principales: | Shi, Lewis Zhichang, Fu, Tihui, Guan, Baoxiang, Chen, Jianfeng, Blando, Jorge M., Allison, James P., Xiong, Liangwen, Subudhi, Sumit K., Gao, Jianjun, Sharma, Padmanee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979067/ https://www.ncbi.nlm.nih.gov/pubmed/27498556 http://dx.doi.org/10.1038/ncomms12335 |
Ejemplares similares
-
Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
por: Hailemichael, Yared, et al.
Publicado: (2014) -
IFNα and IFNγ Impede Marek’s Disease Progression
por: Bertzbach, Luca D., et al.
Publicado: (2019) -
Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
por: Siddiqui, Bilal A., et al.
Publicado: (2022) -
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021) -
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)